NCT06215638进行中（未招募）不适用
An Exploratory Clinical Study on Bortezomib for the Treatment of Refractory Rheumatoid Arthritis
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- ACR20
研究概览
简要总结
The goal of this prospective single-arm open-label trial is to learn about efficacy and safety of Bortezomib in treating patients with difficult-to-treat rheumatoid arthritis. The main questions it aims to answer are:
- Is Bortezomib an effective treatment option for patients with difficult-to-treat rheumatoid arthritis?
- Is Bortezomib safe enough in treating patients with difficult-to-treat rheumatoid arthritis?
Participants will:
- Receive Bortezomib 2 mg per week subcutaneously for twelve weeks in total.
- Follow-up at weeks 4, 12, and 24, while biosamples will be collected.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age >18 years and <70 years;
- •Absolute neutrophil count ≥1.0×10^9/L, platelet count ≥100×10^9/L, aspartate transaminase and total bilirubin within 3 times and 1.5 times the normal upper limit, respectively, and serum creatinine clearance >60 ml/min;
- •Voluntarily sign an informed consent form.
排除标准
- •Individuals with concomitant autoimmune diseases;
- •Presence of severe, poorly controlled cardiovascular, cerebrovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neuropsychiatric diseases, or laboratory abnormalities that the investigator deems an unacceptable risk for the participant's involvement in the study;
- •History of malignant tumors (or clinical cure time less than 5 years);
- •Subjects who are pregnant or lactating, or planning to become pregnant or start breastfeeding during the study period;
- •Vaccination with live virus vaccines within the 4 weeks prior to study entry;
- •Allergy to Borussertib or mannitol;
- •Participation in any other investigational drug trial in the 12 weeks before the start of this study medication;
- •Presence of active hepatitis or a history of severe liver disease at screening: defined as a positive test for hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus antibodies (HCVAb) (Note: If the result of hepatitis B core antibody (HBcAb) is positive and HBsAg is negative, hepatitis B virus (HBV) DNA testing will be performed. If HBV-DNA is negative, the patient is eligible.);
- •Active herpes zoster infection, or occurrence of a severe infection in the 12 weeks before the start of the study medication (defined as requiring intravenous antibiotics or hospitalization);
- •Other situations that investigators deem unsuitable for inclusion.
研究组 & 干预措施
Bortezomib
Experimental
干预措施: Bortezomib (Drug)
结局指标
主要结局
ACR20
时间窗: From enrollment to week 12
The ACR response criteria for 20 percent improvement in disease activity
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Bortezomib for the Treatment of Refractory Rheumatoid ArthritisRheumatoid ArthritisNCT05805891Chinese SLE Treatment And Research Group20
招募中
1 期
Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic CancerPancreas CancerNCT06572813Zhejiang University63
已完成
2 期
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple MyelomaMultiple MyelomaNCT00378209Dana-Farber Cancer Institute65
已完成
不适用
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL AmyloidosisLight Chain Deposition Disease (LCDD or MIDD)Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD)Monoclonal Immunoglobulin Deposition Disease (MIDD)AmyloidosisNCT01383759Memorial Sloan Kettering Cancer Center20
进行中（未招募）
2 期
Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN DeletionMetastatic Castration-resistant Prostate CancerNCT06029998University of Utah22